CN103159730A - Hepatitis-C-resisting drug intermediate preparation method - Google Patents

Hepatitis-C-resisting drug intermediate preparation method Download PDF

Info

Publication number
CN103159730A
CN103159730A CN 201110425505 CN201110425505A CN103159730A CN 103159730 A CN103159730 A CN 103159730A CN 201110425505 CN201110425505 CN 201110425505 CN 201110425505 A CN201110425505 A CN 201110425505A CN 103159730 A CN103159730 A CN 103159730A
Authority
CN
China
Prior art keywords
formula
dimethyl
preparation
adopts
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN 201110425505
Other languages
Chinese (zh)
Inventor
祁小伟
汪秀菊
孟磊
龚彦春
袁方
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Vcare Pharmatech Co Ltd
Original Assignee
Jiangsu Vcare Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Vcare Pharmatech Co Ltd filed Critical Jiangsu Vcare Pharmatech Co Ltd
Priority to CN 201110425505 priority Critical patent/CN103159730A/en
Publication of CN103159730A publication Critical patent/CN103159730A/en
Pending legal-status Critical Current

Links

Images

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention provides a hepatitis-C-resisting drug intermediate preparation method, and relates to a preparation method of (2S, 3R)-3-((R)-2, 2-dimethyl-1, 3-dioxolame-4-base)-2, 3-dyhydroxyl-2-methyl propionic acid methyl ester. The method includes the following steps that: (1) (R)-2, 2-dimethyl-1, 3-dioxolame-4-methanal and 2-(triphenylphosphine alkene)-methyl propionate are subjected to a Wittig reaction to produce (S, E)-3-(2, 2-dimethyl-1, 3-dioxolame-4-goup)-2-methyl methacrylate; (2) a product of the step (1) is subjected to a dihydroxylation to obtain the target compound. The method is simple and convenient to operate, and suitable for industrial production.

Description

A kind of method for preparing anti-the third liver pharmaceutical intermediate
Technical field
The present invention relates to pharmacy field, be specifically related to (2S, 3R)-3-((R)-2,2-dimethyl-DOX-4-yl)-2, the preparation method of 3-dihydroxyl-2 Methylpropionic acid methyl esters.
Background technology
In several new drugs that treatment hepatitis C virus (HCV) infects, PSI-7977 is considered to have extraordinary DEVELOPMENT PROSPECT, and this medicine is in the II phase clinical study stage at present.Sofia etc. are published in J.Med.Chem.2010, disclose the structure (compound 51) of PSI-7977 in the article of 53,7202-7218.
(2S, the 3R)-3-of formula (I) ((R)-2,2-dimethyl-DOX-4-yl)-2,3-dihydroxyl-2 Methylpropionic acid methyl esters are the useful intermediates of preparation PSI-7977.The invention discloses the method for a kind of preparation formula (I), the method reaction conditions is gentle, is suitable for suitability for industrialized production.
Summary of the invention
The invention provides the preparation method of a kind of formula (I) compound, be shown below:
Figure BSA00000638267900011
Aforesaid method specifically comprises the following steps:
(1) with (R)-2 of formula (II), 2-dimethyl-1,2 (triphenylphosphine alkene)-methyl propionates of 3-dioxolane-4-formaldehyde and formula (III) are through (the S of Wittig reaction production (IV), E)-3-(2,2-dimethyl-DOX-4-yl)-2-methyl methacrylate;
(2) formula (IV) compound is carried out dihydroxylation reaction, make formula (I) compound.
In above-mentioned steps (1), the solvent that adopts can be aprotic solvent or any mixed solvents wherein such as tetrahydrofuran (THF), acetonitrile, dioxan, methylene dichloride, ether, acetone, toluene, more preferably methylene dichloride; The temperature of reaction that adopts is-78~40 ℃, more preferably-5~5 ℃.
In above-mentioned steps (2), the dihydroxylation oxygenant that adopts can be potassium permanganate, Manganse Dioxide or hydrogen peroxide, preferred potassium permanganate; Preferred 1: 4 of the mol ratio of formula IV compound and oxygenant, more preferably 1: 1~1.2; The solvent that adopts can be the mixed solvent of acetone, tetrahydrofuran (THF) or acetonitrile and water, and the volume ratio of preferred acetone and water is 9: 1, and the weightmeasurement ratio of raw material and mixed solvent is 1: 10; The temperature of reaction that adopts is-20~40 ℃, more preferably-5~5 ℃.
Description of drawings
Fig. 1 is (2S, 3R)-3-((R)-2,2-dimethyl-DOX-4-yl)-2, the proton nmr spectra of 3-dihydroxyl-2 Methylpropionic acid methyl esters;
Fig. 2 is (2S, 3R)-3-((R)-2,2-dimethyl-DOX-4-yl)-2, the mass spectrum of 3-dihydroxyl-2 Methylpropionic acid methyl esters.
Embodiment
Further describe by the following examples the present invention, summary of the invention comprises but is not limited to concrete embodiment.
Embodiment 1
The preparation of (S, E)-3-(2,2-dimethyl-DOX-4-yl)-2-methyl methacrylate
At room temperature, 2-(triphenylphosphine alkene)-methyl propionate (6.3kg) is dissolved in methylene dichloride (20L), 0-5 ℃ slowly drips (R)-2,2-dimethyl-1, methylene dichloride (6L) solution of 3-dioxolane-4-formaldehyde (2.5kg), dropwise, naturally rise to room temperature, reacted 4 hours.Reaction solution is concentrated into dried, adds sherwood oil (40L) under stirring, have a large amount of white solids to separate out, suction filtration obtains crude product (S, E) 3 (2,2 dimethyl-1,3 dioxolane-4-yl)-2-methyl methacrylate (4.1kg), not purified next step reaction of direct input.
Embodiment 2
(2S, 3R)-3-((R)-2,2-methyl isophthalic acid, 3-dioxolane-4-yl)-2, the preparation of 3-dihydroxyl-2 Methylpropionic acid methyl esters
With (S, E) 3 (2,2 dimethyl-1,3 dioxolane 4 bases) 2 methyl methacrylates (4.1kg) are dissolved in the mixing solutions of acetone (37L) and water (4.1L), add potassium permanganate (3.87kg) in the time of 05 ℃ in batches, control temperature and be no more than 20 ℃, add insulation 4 hours.Add solid sodium sulfite (4kg) and water (15L) in reaction solution, stirred 30 minutes.Suction filtration, filter cake respectively washs once with 2L acetone and 2L water.Filtrate decompression is concentrated into acetone and substantially removes, and adds solid sodium chloride to saturated in residual solution, then uses ethyl acetate (8LX3) extraction.Merge organic layer, concentrated, get colourless liquid (2.5kg), under stirring, this liquid is poured in water (12L), crystallization, suction filtration, filter cake discards, filtrate, add solid sodium chloride to saturated, then use ethyl acetate (6LX3) extraction, merge organic layer, concentrate to get white solid 2kg.Under 55 ℃, with the mixed solvent recrystallization of ethyl acetate (4L) and sherwood oil (16L), be cooled to 0-5 ℃ and kept 4 hours, suction filtration, washing, the filter cake oven dry gets (2S, 3R)-3-((R)-2,2-dimethyl-DOX-4-yl)-2,3-dihydroxyl-2 Methylpropionic acid methyl esters (980g), white solid, purity is more than 99%.HNMR(300MHz,DMSO-d6)δ5.16(1H,d,J=9Hz),5.01(1H,s),4.13(1H,m),3.89(2H,m),3.67(1H,m),3.62(3H,s),1.29(3H,s),1.27(3H,s),1.25(3H,s).

Claims (7)

1. one kind prepares (2S, the 3R)-3-shown in compound formula (I) ((R)-2,2-dimethyl-DOX-4-yl)-2, the method for 3-dihydroxyl-2 Methylpropionic acid methyl esters:
Figure FSA00000638267800011
Specifically comprise the steps:
(1) with (R)-2 of formula (II), 2-dimethyl-1, the 2-of 3-dioxolane-4-formaldehyde and formula (III) (triphenylphosphine alkene)-methyl propionate is through (the S of Wittig reaction production (IV), E)-3-(2,2-dimethyl DOX-4-yl)-2-methyl methacrylate:
Figure FSA00000638267800012
(2) formula (IV) compound is carried out dihydroxylation reaction, make formula (I) compound.
2. preparation method according to claim 1, it is characterized in that, in the step (1) of claim 1, the solvent that adopts can be aprotic solvent or any mixed solvents wherein such as tetrahydrofuran (THF), acetonitrile, dioxan, methylene dichloride, ether, acetone, toluene, more preferably methylene dichloride.
3. according to claim 1 with 2 described preparation methods, is characterized in that, in the step (1) of claim 1, the temperature of reaction that adopts is-78~40 ℃, more preferably-5~5 ℃.
4. preparation method according to claim 1, is characterized in that, in the step (2) of claim 1, the dihydroxylation oxygenant that adopts can be potassium permanganate, Manganse Dioxide or hydrogen peroxide, preferred potassium permanganate; Preferred 1: 4 of the mol ratio of formula IV compound and oxygenant, more preferably 1: 1~1.2.
5. preparation method according to claim 1, it is characterized in that, in the step (2) of claim 1, the solvent that adopts can be the mixed solvent of acetone, tetrahydrofuran (THF) or acetonitrile and water, the volume ratio of preferred acetone and water is 9: 1, and the weightmeasurement ratio of raw material and mixed solvent is 1: 10.
6. preparation method according to claim 1, is characterized in that, in the step (2) of claim 1, the temperature of reaction that adopts is-20~40 ℃, more preferably-5~5 ℃.
7. (2S, the 3R)-3-shown in compound formula (I) ((R)-2,2-dimethyl-DOX-4-yl)-2,3-dihydroxyl-2 Methylpropionic acid methyl esters:
Figure FSA00000638267800021
CN 201110425505 2011-12-19 2011-12-19 Hepatitis-C-resisting drug intermediate preparation method Pending CN103159730A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 201110425505 CN103159730A (en) 2011-12-19 2011-12-19 Hepatitis-C-resisting drug intermediate preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 201110425505 CN103159730A (en) 2011-12-19 2011-12-19 Hepatitis-C-resisting drug intermediate preparation method

Publications (1)

Publication Number Publication Date
CN103159730A true CN103159730A (en) 2013-06-19

Family

ID=48583297

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 201110425505 Pending CN103159730A (en) 2011-12-19 2011-12-19 Hepatitis-C-resisting drug intermediate preparation method

Country Status (1)

Country Link
CN (1) CN103159730A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104478845A (en) * 2014-12-02 2015-04-01 浙江九洲药业股份有限公司 Preparation method of fluorine lactone intermediate

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104478845A (en) * 2014-12-02 2015-04-01 浙江九洲药业股份有限公司 Preparation method of fluorine lactone intermediate
CN104478845B (en) * 2014-12-02 2016-04-13 浙江九洲药业股份有限公司 A kind of preparation method of fluorine lactone intermediate

Similar Documents

Publication Publication Date Title
CN105330609B (en) A kind of method for preparing LCZ696
CN104628773B (en) (R)-9-[2- (phosphinylidyne phenol ylmethoxy) propyl;The preparation method of adenine
CN104487436B (en) Improved process for preparing rivaroxaban using intermediates
CN109574961B (en) Method for preparing sofosbuvir intermediate
CN104781243A (en) (2r)-2-deoxy-2,2-disubstitute-1,4-ribose lactone and preparation method and use thereof
CN103435592B (en) 2-((4R,6S)-6-formaldehyde-2,2-dimethyl-1,3 dioxane-4-base)-methyl acetate preparation method
JP6174161B2 (en) Method for producing 2-aminonicotinic acid benzyl ester derivative
CN103159730A (en) Hepatitis-C-resisting drug intermediate preparation method
CN105175346A (en) Method for synthesis of rosuvastatin calcium intermediate
CN103804414B (en) For the preparation of rosuvastain calcium midbody compound and prepared the method for rosuvastain calcium by it
CN105732648A (en) Nitrogen heterocyclic ring compound of pyrrolofuran and synthetic method
CN106928149A (en) A kind of preparation method of olaparib
CN109369553B (en) Method for synthesizing N-3-isoxazole carbamic acid tert-butyl ester
CN105017158B (en) A kind of preparation method of cis Rosuvastatin calcium impurities
CN103073525A (en) Method for synthesizing (S)-(3,4-difluorophenyl)hexamethylene oxide
CN105330525A (en) Preparation method of 7-hydroxy-1-indanone
CN105566424A (en) Method for preparing calcium dibutyryladenosine cyclophosphate
CN105273001A (en) Synthetic method of phosphatidyl glycerol monosodium salt
CN105461634A (en) Preparation method of enzalutamide
CN102875460A (en) Method for preparing sorafenib
CN103755617A (en) Method for preparing key impurity of ezetimibe
CN103360254A (en) Production method of alpha-chlorine (2-chlorine) methyl phenylacetate
CN102731292B (en) Preparation method of levo-flurbiprofen
CN104193656B (en) A kind of beta-dicarbonyl sulfone compound and preparation method thereof
CN102557941B (en) Preparation method for intermediate compound of derivative of spiro-propyl formyl

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C05 Deemed withdrawal (patent law before 1993)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130619